Genetically modified stem cells target recurrent brain cancer
NCT ID NCT02192359
First seen Nov 15, 2025 · Last updated May 08, 2026 · Updated 26 times
Summary
This early-phase trial tests a new approach for people with high-grade gliomas that have returned after prior treatment. Genetically modified neural stem cells are placed directly into the brain tumor to make it more sensitive to the chemotherapy drug irinotecan. The main goal is to find the safest dose and understand side effects. About 18 adults with recurrent glioblastoma or similar brain cancers are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.